5T4 oncofetal antigen expression in ovarian carcinoma

5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:International journal of gynecological cancer 1995-07, Vol.5 (4), p.269-274
Hauptverfasser: WRIGLEY, E., McGOWN, A.T., RENNISON, J., SWINDELL, R., CROWTHER, D., STARZYNSKA, T., STERN, P.L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 274
container_issue 4
container_start_page 269
container_title International journal of gynecological cancer
container_volume 5
creator WRIGLEY, E.
McGOWN, A.T.
RENNISON, J.
SWINDELL, R.
CROWTHER, D.
STARZYNSKA, T.
STERN, P.L.
description 5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P < 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease- free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.
doi_str_mv 10.1046/j.1525-1438.1995.05040269.x
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1859356853</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1048891X24062650</els_id><sourcerecordid>2552794085</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5155-42b9cd49226192a673f03769d3cded2175f2f26f7b6b094a44a46686909b5d7a3</originalsourceid><addsrcrecordid>eNqVUU1v1DAUtBCItgt_AUXqhUuC7fhTnFAppahSL0XiZjnOC_WStRc7abf_vo52CxInKlmynz0zbzwPoVOCG4KZ-LBuCKe8JqxVDdGaN5hjhqnQze4FOv7z9rKcMVO10uTHETrJeY0x1hTr1-iIEC4VU-oYcX7DqhhcHGCyY2XD5H9CqGC3TZCzj6HyoYp3NnkbKmeT8yFu7Bv0arBjhreHfYW-fzm_OftaX11fXJ59uqodJ5zXjHba9UxTKoimVsh2wK0Uum9dDz0lkg90oGKQneiwZpaVJYQSGuuO99K2K_R-r7tN8fcMeTIbnx2Mow0Q52yI4rrlQvG2QE__ga7jnEJxZyjnVGqGC2yFPu5RLsWcEwxmm_zGpgdDsFnSNWuzJGiWBM2SrnlK1-wK-92hx9xtoP_LPcRZAGwPuI_jBCn_Gud7SOYW7DjdGrwMgEtZL7pYlqperhZXnw80P8LDcyyZy28XT1WROd_LQBnJnS-Ns_MQHPQ-gZtMH_1_ffMRVSatDw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552794085</pqid></control><display><type>article</type><title>5T4 oncofetal antigen expression in ovarian carcinoma</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>WRIGLEY, E. ; McGOWN, A.T. ; RENNISON, J. ; SWINDELL, R. ; CROWTHER, D. ; STARZYNSKA, T. ; STERN, P.L.</creator><creatorcontrib>WRIGLEY, E. ; McGOWN, A.T. ; RENNISON, J. ; SWINDELL, R. ; CROWTHER, D. ; STARZYNSKA, T. ; STERN, P.L.</creatorcontrib><description>5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P &lt; 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease- free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.</description><identifier>ISSN: 1048-891X</identifier><identifier>EISSN: 1525-1438</identifier><identifier>DOI: 10.1046/j.1525-1438.1995.05040269.x</identifier><identifier>PMID: 11578488</identifier><language>eng</language><publisher>Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts 02142, USA: Elsevier Inc</publisher><subject>5T4 oncofetal antigen ; Antigens ; Cancer ; Medical prognosis ; Ovarian cancer ; ovarian carcinoma ; Ovaries ; survival ; Tumors</subject><ispartof>International journal of gynecological cancer, 1995-07, Vol.5 (4), p.269-274</ispartof><rights>1995 Blackwell Science Ltd.</rights><rights>1995 1995 Blackwell Science Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5155-42b9cd49226192a673f03769d3cded2175f2f26f7b6b094a44a46686909b5d7a3</citedby><cites>FETCH-LOGICAL-c5155-42b9cd49226192a673f03769d3cded2175f2f26f7b6b094a44a46686909b5d7a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1046%2Fj.1525-1438.1995.05040269.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1046%2Fj.1525-1438.1995.05040269.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11578488$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>WRIGLEY, E.</creatorcontrib><creatorcontrib>McGOWN, A.T.</creatorcontrib><creatorcontrib>RENNISON, J.</creatorcontrib><creatorcontrib>SWINDELL, R.</creatorcontrib><creatorcontrib>CROWTHER, D.</creatorcontrib><creatorcontrib>STARZYNSKA, T.</creatorcontrib><creatorcontrib>STERN, P.L.</creatorcontrib><title>5T4 oncofetal antigen expression in ovarian carcinoma</title><title>International journal of gynecological cancer</title><addtitle>Int J Gynecol Cancer</addtitle><description>5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P &lt; 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease- free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.</description><subject>5T4 oncofetal antigen</subject><subject>Antigens</subject><subject>Cancer</subject><subject>Medical prognosis</subject><subject>Ovarian cancer</subject><subject>ovarian carcinoma</subject><subject>Ovaries</subject><subject>survival</subject><subject>Tumors</subject><issn>1048-891X</issn><issn>1525-1438</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1995</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqVUU1v1DAUtBCItgt_AUXqhUuC7fhTnFAppahSL0XiZjnOC_WStRc7abf_vo52CxInKlmynz0zbzwPoVOCG4KZ-LBuCKe8JqxVDdGaN5hjhqnQze4FOv7z9rKcMVO10uTHETrJeY0x1hTr1-iIEC4VU-oYcX7DqhhcHGCyY2XD5H9CqGC3TZCzj6HyoYp3NnkbKmeT8yFu7Bv0arBjhreHfYW-fzm_OftaX11fXJ59uqodJ5zXjHba9UxTKoimVsh2wK0Uum9dDz0lkg90oGKQneiwZpaVJYQSGuuO99K2K_R-r7tN8fcMeTIbnx2Mow0Q52yI4rrlQvG2QE__ga7jnEJxZyjnVGqGC2yFPu5RLsWcEwxmm_zGpgdDsFnSNWuzJGiWBM2SrnlK1-wK-92hx9xtoP_LPcRZAGwPuI_jBCn_Gud7SOYW7DjdGrwMgEtZL7pYlqperhZXnw80P8LDcyyZy28XT1WROd_LQBnJnS-Ns_MQHPQ-gZtMH_1_ffMRVSatDw</recordid><startdate>199507</startdate><enddate>199507</enddate><creator>WRIGLEY, E.</creator><creator>McGOWN, A.T.</creator><creator>RENNISON, J.</creator><creator>SWINDELL, R.</creator><creator>CROWTHER, D.</creator><creator>STARZYNSKA, T.</creator><creator>STERN, P.L.</creator><general>Elsevier Inc</general><general>Blackwell Science Ins</general><general>Blackwell Science Ltd</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>199507</creationdate><title>5T4 oncofetal antigen expression in ovarian carcinoma</title><author>WRIGLEY, E. ; McGOWN, A.T. ; RENNISON, J. ; SWINDELL, R. ; CROWTHER, D. ; STARZYNSKA, T. ; STERN, P.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5155-42b9cd49226192a673f03769d3cded2175f2f26f7b6b094a44a46686909b5d7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1995</creationdate><topic>5T4 oncofetal antigen</topic><topic>Antigens</topic><topic>Cancer</topic><topic>Medical prognosis</topic><topic>Ovarian cancer</topic><topic>ovarian carcinoma</topic><topic>Ovaries</topic><topic>survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>WRIGLEY, E.</creatorcontrib><creatorcontrib>McGOWN, A.T.</creatorcontrib><creatorcontrib>RENNISON, J.</creatorcontrib><creatorcontrib>SWINDELL, R.</creatorcontrib><creatorcontrib>CROWTHER, D.</creatorcontrib><creatorcontrib>STARZYNSKA, T.</creatorcontrib><creatorcontrib>STERN, P.L.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of gynecological cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>WRIGLEY, E.</au><au>McGOWN, A.T.</au><au>RENNISON, J.</au><au>SWINDELL, R.</au><au>CROWTHER, D.</au><au>STARZYNSKA, T.</au><au>STERN, P.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>5T4 oncofetal antigen expression in ovarian carcinoma</atitle><jtitle>International journal of gynecological cancer</jtitle><addtitle>Int J Gynecol Cancer</addtitle><date>1995-07</date><risdate>1995</risdate><volume>5</volume><issue>4</issue><spage>269</spage><epage>274</epage><pages>269-274</pages><issn>1048-891X</issn><eissn>1525-1438</eissn><abstract>5T4 oncofetal antigen is defined by a monoclonal antibody raised against human placental trophoblast, and recognizes a 72 kD glycoprotein expressed in many different carcinomas but detected only at low levels in some normal epithelia. Analysis of the patterns of expression of 5T4 oncofetal antigen in colorectal carcinomas has indicated a significant association between the presence of the antigen in tumor cells and metastatic spread. The 5T4 antigen expression of 72 epithelial ovarian carcinomas has been investigated by immunohistochemistry; 71% of the carcinomas demonstrated positive 5T4 immunoreactivity in adenocarcinoma cells and/or associated stromal tissue. In order to assess any relationship to prognosis, the 5T4 phenotypes were analyzed with respect to various clinicopathologic features of the tumors and the clinical outcome of the patients assessed by survival and disease-free interval. There was a significant correlation between 5T4 expression and more advanced stage of disease (FIGO stages III and IV) (P &lt; 0.001) and with poorly differentiated tumors (P = 0.036) compared to well or moderately differentiated tumors. Patients with tumors expressing 5T4 were less likely to respond well to adjuvant therapy (P = 0.030) and had a significantly worse outlook in terms of survival (P = 0.033) and disease- free interval (P = 0.033). This significance was not demonstrated as acting independently of FIGO stage and tumor differentiation.</abstract><cop>Suite 500, 5th Floor, 238 Main Street, Cambridge, Massachusetts 02142, USA</cop><pub>Elsevier Inc</pub><pmid>11578488</pmid><doi>10.1046/j.1525-1438.1995.05040269.x</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1048-891X
ispartof International journal of gynecological cancer, 1995-07, Vol.5 (4), p.269-274
issn 1048-891X
1525-1438
language eng
recordid cdi_proquest_miscellaneous_1859356853
source Wiley Online Library Journals Frontfile Complete
subjects 5T4 oncofetal antigen
Antigens
Cancer
Medical prognosis
Ovarian cancer
ovarian carcinoma
Ovaries
survival
Tumors
title 5T4 oncofetal antigen expression in ovarian carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T18%3A41%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=5T4%20oncofetal%20antigen%20expression%20in%20ovarian%20carcinoma&rft.jtitle=International%20journal%20of%20gynecological%20cancer&rft.au=WRIGLEY,%20E.&rft.date=1995-07&rft.volume=5&rft.issue=4&rft.spage=269&rft.epage=274&rft.pages=269-274&rft.issn=1048-891X&rft.eissn=1525-1438&rft_id=info:doi/10.1046/j.1525-1438.1995.05040269.x&rft_dat=%3Cproquest_cross%3E2552794085%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552794085&rft_id=info:pmid/11578488&rft_els_id=S1048891X24062650&rfr_iscdi=true